MedTrace Logo

Assessment of Alcon's Ocular Image Quantification System

NCT01282138 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2012-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate ocular responses with different allergen provocation methods.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)

One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.

OTHER

Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)

One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282138 on ClinicalTrials.gov